To evaluate the short-term clinical results and safety of Ultra Q neodymium-doped yttrium aluminium garnet (Nd:YAG) laser treatment for vitreous floaters. Methods: The present study included 31 eyes of 31 patients with symptomatic floaters lasting more than 3 months. The vitreous floaters were photodisrupted using Ultra Q Nd:YAG laser. Preoperative and postoperative best corrected visual activity (BCVA) and intraocular pressure, change of the floater, patient satisfaction and postoperative complications were analyzed prospectively. Results: There was no significant difference between preoperative and postoperative BCVA and intraocular pressure (p > 0.05). Vitreous floaters were not found in 9 eyes (29.03%), decreased floaters were observed in 19 eyes (61.29%) and definite change of floaters was not observed in 3 eyes (9.68%). Patient satisfaction after the laser treatment was very satisfied in 11 eyes (35.48%) and satisfied in 20 eyes (64.58%). Satisfaction in Weiss ring type of the floater was the highest, very satisfied in 6 of the 8 eyes (75%) and vitreous floaters were not observed in 7 of the 8 eyes (87.50%). Postoperative complications were not observed during a follow-up period of at least 3 months. Conclusions: Ultra Q Nd:YAG laser was an effective and safe treatment for the vitreous floaters in this short-term study. J Korean Ophthalmol Soc 2015;56(6):885-890
Values are presented as mean ± SD unless otherwise indicated. OD = oculus dexter; OS = oculus sinister. Values are presented as mean ± SD. BCVA = best corrected visual acuity; IOP = intraocular pressure; log MAR = logarithm of the minimum angle of resolution. Values are presented as n (%). Values are presented as n (%). 
